<DOC>
	<DOCNO>NCT03092635</DOCNO>
	<brief_summary>The purpose study look effect study drug ( metformin OPC ) AGE level patient ER+ metastatic breast cancer .</brief_summary>
	<brief_title>AGE Levels ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy</brief_title>
	<detailed_description>AGEs type metabolite , substance , find food . The AGE content food determine type food eat also prepare food . The researcher help conduct study find potential link AGE level cancer . The purpose study see certain drug ( metformin OPC ) effect AGE level blood see AGE level effect cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Must ER+ breast cancer Metastatic disease ; protocol allow boneonly disease Must receive endocrine therapy Must complete last 2 month current endocrine therapy prior registration Must adequate hematologic , renal hepatic function Prior/concurrent radiation therapy allow Prior chemotherapy allow , last dose must least 2 month prior enrollment May diabetes , must take metformin Must able swallow retain oral medication Performance status 02 Treated stable brain metastasis allow , long patient require steroid antiseizure medication Must inform investigational nature study must ability sign inform consent . Known allergy grape grape seed Known hypersensitivity intolerance metformin Any condition associate increase risk metforminassociated lactic acidosis ( e.g. , congestive heart failure define New York Heart Association { NYHA } Class III IV functional status ; history acidosis type ; habitual intake 3 alcoholic beverage per day ) . More two prior endocrine therapy regimens treatment metastatic ER+ breast cancer . Concurrent use restrict agent outline section 4.5 . History alcohol abuse within 2 year registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>